Haemonetics (HAE) closed the last trading session at $88.64, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $112.20 indicates a 26.6% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $12.15. While the lowest estimate of $94 indicates a 6.1% increase from the current price level, the most optimistic analyst expects ...

关于Haemonetics公司评级升级 - Haemonetics被升级为Zacks Rank 1（强力买入）这一评级变化反映了盈利预期的上升趋势是影响股价最有力的因素之一[1] - 公司的盈利状况是Zacks评级的唯一决定因素系统会跟踪覆盖该股票的卖方分析师对当前和未来几年每股收益预期的共识即Zacks共识预期[2] - 个体投资者很难根据华尔街分析师的评级升级做决策因为这些大多受主观因素驱动而Zacks评级系统因盈利状况对近期股价走势的影响力而派上用场[3] - Zacks对Haemonetics的评级升级本质上是对其盈利前景的积极评价可能对其股价产生有利影响[4] 盈利预期与股价关系 - 公司未来盈利潜力的变化（反映在盈利预期修正中）与其股票的近期价格走势被证明是强相关的部分原因是机构投资者利用盈利和盈利预期来计算公司股票的公允价值[5] - 对于Haemonetics上升的盈利预期和随之而来的评级升级从根本上意味着公司基础业务的改善投资者对这种业务改善趋势的认可应会推动股价上涨[6] - 实证研究表明盈利预期修正趋势与近期股票走势之间存在强相关性Zacks Rank股票评级系统有效利用了盈利预期修正的力量[7] Zacks Rank股票评级系统 - Zacks Rank股票评级系统使用与盈利预期相关的四个因素将股票分为五组从Zacks Rank 1（强力买入）到Zacks Rank 5（强力卖出）自1988年以来Zacks Rank 1股票平均年回报率为+25%[8] - 与华尔街分析师不同Zacks评级系统在任何时候对其涵盖的4000多只股票都保持相同比例的买入和卖出评级只有排名前5%的股票能获得强力买入评级下一个15%获得买入评级[11] Haemonetics公司盈利预期修正情况 - 截至2025年3月的财年这家为医疗保健提供商和采血机构提供血液管理系统的公司预计每股盈利4.46美元较上年报告数字变化12.6%[9] - 在过去三个月里对该公司的Zacks共识预期增长了9.8%[10] 关于Haemonetics评级升级的结论 - Haemonetics升级为Zacks Rank 1使其在估计修正方面位于Zacks覆盖股票的前5%这意味着该股票在近期可能会上涨[13]

BOSTON, May 23, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased from the previously announced offering size of $525,000,000 aggregate principal amo ...

Haemonetics (HAE) is well-poised to grow in the coming quarters, backed by the strong potential of the Plasma franchise. The company’s hospital portfolio is evolving and helping create new opportunities for growth and diversification. Strong financial stability also buoys optimism.Meanwhile, headwinds from economic uncertainties and adverse foreign exchange effects are concerns for Haemonetics’ operations.In the past year, this Zacks Rank #2 (Buy) stock has rallied 11.7% against the 1.3% fall of the industr ...

BOSTON, May 21, 2024 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions, $525,000,000 aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").  Haemonetics also expects to grant the initial purchasers of the notes an option to purc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorpor ...

Haemonetics (HAE) continues to expand its business, banking on growth drivers like Plasma, Thromboelastography (TEG), Hemostasis Management and the Vascular Closure business. The stock sports a Zacks Rank #1 (Strong Buy).Haemonetics’ Plasma business unit focuses on the collection of source plasma for pharmaceutical manufacturers using apheresis devices that only collect plasma. The demand for source plasma has continued to grow due to an expanding end-user market for plasma-derived biopharmaceuticals. The b ...

关于Haemonetics公司 - 公司股票年初至今上涨10.8%高于行业6.1%的涨幅医疗板块涨幅为1%公司市值48.2亿美元[1] - 过去几个季度持续增长业绩反映出其战略重点是在高增长市场建立领先地位以产生稳健财务回报这可能推动这一Zacks排名1（强力买入）的股票[2] - 预计未来五年收益增长12%公司过去12个月的ROE为4.6%优于行业平均0.2%[3] - Zacks对公司2025年收益的共识估计为1.40美元较上年报告数字增长6.9%对2025年营收的共识估计为44.6亿美元同比增长12.6%[4] - 公司新推出的Express Plus技术在有限市场发布后获得成功有超过6万次实际应用目前正在美国启动全面市场发布该技术正在快速吸引新客户[5] - 公司的Persona专有技术平均将产量从9%提高到12%其推广持续获得动力有超过2500万次应用管理层指出从PCS2设备向带有Persona技术的NexSys设备的持续过渡将在2025年带来显著改善[6] - 在血管闭合方面公司有望在本财年结束时进入美国600家目标顶级医院账户中的80%公司还获得了FDA对加大尺寸的VASSCADE MVPXL中孔静脉闭合装置的上市前批准这将加强公司在高增长市场的影响力[7] - 国际上公司产品正在获得吸引力VASCADE国际发布进展符合预期在第四财季贡献了约30个百分点的营收增长[8] - 止血管理增长继续受到TEG 6s一次性用品的高利用率价格上涨和美国装机量持续增长的推动公司在第四财季还获得了FDA对其全球止血肝素中和盒的批准这有助于增加产品采用率[9] - 公司预计将保持增长势头利用大幅扩展的研发和临床能力开发新产品和现有产品并构建商业基础设施以覆盖7亿美元未充分渗透的总可寻址市场中的大部分战略客户[10] - 公司对2025年的预期总GAAP营收增长在5 - 8%有机营收增长预期在0 - 3%预计2025年全年调整后每股收益在4.45 - 4.75美元之间[11] - 过去90天Zacks对公司2025年和2026年的共识估计分别上升16.5%和22%反映出分析师的乐观态度[12] 关于其他医疗公司 - Medpace Zacks排名1 2024年第一季度每股收益3.20美元超出Zacks共识估计30.6%营收5.11亿美元较去年同期增长17.7%预计2024年收益增长率为26.5%高于行业12.3%过去四个季度收益均超出估计平均超出12.8%[14][15] - ResMed Zacks排名2 2024年第一季度每股收益2.13美元超出Zacks共识估计10.9%营收12亿美元超出Zacks共识估计1.9%预计2024财年收益增长率为17.9%高于行业15.7%过去四个季度平均收益超出2.8%[16][17] - Encompass Health Zacks排名2 2024年第一季度调整后每股收益1.12美元超出Zacks共识估计20.4%净营业收入13亿美元超出Zacks共识估计3.6%预计长期收益增长率为15.6%高于行业11.7%过去四个季度收益均超出估计平均超出18.7%[18][19]

Shares of Haemonetics (HAE) have been strong performers lately, with the stock up 13.4% over the past month. The stock hit a new 52-week high of $97.35 in the previous session. Haemonetics has gained 12.5% since the start of the year compared to the 3.8% move for the Zacks Medical sector and the 2.9% return for the Zacks Medical - Products industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Sc ...